Advertisement

Topics

Synspira Company Profile

17:59 EDT 18th March 2019 | BioPortfolio

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform for the development of inhaled glycopolymer-based therapeutics in pulmonary indications. Synspira is using proprietary modified polysaccharide molecules to disrupt bacterial biofilms and to help expectorate mucus, exposing otherwise protected bacteria to antibiotics. This new approach to the treatment of disease pathology has the potential to improve pulmonary function and reduce antibiotic resistance in a number of infectious diseases. www.synspira.com


News Articles [5 Associated News Articles listed on BioPortfolio]

FDA Grants Orphan Drug Designation to Synspira’s Investigational Cystic Fibrosis Therapy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announce...

Synspira’s abstracts accepted for presentation at the 32nd Annual NACFC

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that three abstracts have been accepted for...

Synspira Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications ...

MacDougall Biomedical CommunicationsAmanda Houlihan, 781-235-3060ahoulihan@macbiocom.com Read more...

Synspira Receives U.S. FDA Orphan Designation for PAAG15A for the Treatment of Cystic Fibrosis

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that it has bee...

Synspira Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that three abst...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases i...

More Information about "Synspira" on BioPortfolio

We have published hundreds of Synspira news stories on BioPortfolio along with dozens of Synspira Clinical Trials and PubMed Articles about Synspira for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Synspira Companies in our database. You can also find out about relevant Synspira Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...


Corporate Database Quicklinks



Searches Linking to this Company Record